This HTML5 document contains 62 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n24http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n13http://linked.opendata.cz/resource/drugbank/company/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00896/identifier/wikipedia/
n26http://linked.opendata.cz/resource/drugbank/dosage/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00896/identifier/pharmgkb/
n18http://bio2rdf.org/drugbank:
n15http://linked.opendata.cz/resource/drugbank/drug/DB00896/identifier/pubchem-compound/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00896/identifier/pubchem-substance/
admshttp://www.w3.org/ns/adms#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00896/identifier/kegg-drug/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00896/identifier/drugbank/
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n25http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00896/identifier/national-drug-code-directory/
n3http://linked.opendata.cz/ontology/drugbank/
n21http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00896/identifier/chemspider/
n10http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00896
rdf:type
n3:Drug
n3:description
Rimexolone is a glucocorticoid steroid used to treat inflammation in the eye. It is marketed as a 1% eye drop solution under the trade name Vexol
n3:dosage
n26:271B59D6-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
The serum half-life of rimexolone could not be reliably estimated due to the large number of samples below the quantitation limit of the assay (80 pg/mL). However, based on the time required to reach steady-state, the half-life appears to be short (1-2 hours).
n3:indication
For the treatment of postoperative inflammation following ocular surgery and in the treatment of anterior uveitis.
n3:manufacturer
n13:271B59D2-363D-11E5-9242-09173F13E4C5
owl:sameAs
n12:DB00896 n18:DB00896
dcterms:title
Rimexolone
adms:identifier
n7:Rimexolone n8:PA164752251 n15:39507 n16:46504820 n17:0065-0627-07 n19:D05729 n22:36120 n23:DB00896
n3:mechanismOfAction
Rimexolone is a glucocorticoid receptor agonist. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition of arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. By binding to the glucocorticoid receptor, this drug ultimately leads to changes in genetic transcription involving the lipocortins and prostaglandins.
n3:packager
n13:271B59D1-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Following IV administration of radio-labelled rimexolone to rats, greater than 80% of the dose is excreted via the feces as rimexolone and metabolites.
n3:toxicity
Symptoms of overdose include retinal toxicity, glaucoma, and subcapsular cataract.
n9:hasAHFSCode
n14:52-08-08
foaf:page
n21:rimexolone.html n24:rimexol.htm
n3:IUPAC-Name
n4:271B59DB-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B59E1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B59E0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B59DD-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B59DE-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B59DF-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B59F1-363D-11E5-9242-09173F13E4C5 n4:271B59D9-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B59DA-363D-11E5-9242-09173F13E4C5 n4:271B59F2-363D-11E5-9242-09173F13E4C5 n4:271B59D7-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B59D8-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n10:S01BA13 n10:H02AB12
n3:H-Bond-Acceptor-Count
n4:271B59E7-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B59E8-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B59E2-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B59E3-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B59E5-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B59E4-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B59E6-363D-11E5-9242-09173F13E4C5
n3:absorption
Systemically absorbed.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
49697-38-3
n3:category
n3:containedIn
n25:271B59D3-363D-11E5-9242-09173F13E4C5 n25:271B59D4-363D-11E5-9242-09173F13E4C5 n25:271B59D5-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B59ED-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B59EF-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B59F0-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B59EC-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B59EB-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B59EE-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B59DC-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B59E9-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B59EA-363D-11E5-9242-09173F13E4C5